RECRUITING

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Talk to us

Conditions

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh-grade B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Transformed Follicular Lymphoma (tFL)Follicular Lymphoma Grade 3B

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Official Title

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies

Quick Facts

Study Start:2024-04-16
Study Completion:2041-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06014762

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Angie Schinkel
CONTACT
858-779-3103
clinicaltrials@poseida.com

Principal Investigator

Rajesh Belani, MD
STUDY_DIRECTOR
Vice President, Clinical Development

Study Locations (Sites)

University of California San Diego
La Jolla, California, 92093
United States
Loma Linda University Cancer Center
Loma Linda, California, 92354
United States
Wayne State - Karmanos Cancer Institute
Detroit, Michigan, 48201
United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
United States
University of Cincinnati
Cincinnati, Ohio, 45206
United States
University of Oklahoma, Health Sciences Center
Oklahoma City, Oklahoma, 73104
United States
Prisma Health - Upstate Cancer Institute
Greenville, South Carolina, 29605
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
Baylor Scott & White Research Institute
Dallas, Texas, 75204
United States

Collaborators and Investigators

Sponsor: Poseida Therapeutics, Inc.

  • Rajesh Belani, MD, STUDY_DIRECTOR, Vice President, Clinical Development

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-16
Study Completion Date2041-03

Study Record Updates

Study Start Date2024-04-16
Study Completion Date2041-03

Terms related to this study

Additional Relevant MeSH Terms

  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • High-grade B-cell Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Transformed Follicular Lymphoma (tFL)
  • Follicular Lymphoma Grade 3B